GENE ONLINE|News &
Opinion
Blog

Market Insight on FDA-approvals: Rise of First-in-class and Regenerative Innovations

by GeneOnline
Share To
Achieving market entry for new drugs has never been more challenging,  especially for non-COVID medications during a time shrouded in COVID-19. Notably, the US FDA has pushed to accelerate the launches of non-COVID medications and has been reviewing more next-generation (Next-Gen) drugs in the last 14 months. Next-Gen drugs, here chiefly describing the first-in-class and regeneration ones which encompass strong clinical benefits and market competitions, are evolving fast year on year.

GO Prime with only $1.49 now

LATEST
Flagship-Backed ProFound Launches With $75 Million to Discover Human Proteins
2022-05-27
Janssen’s First Cell Therapy Gets Europe’s Approval for Multiple Myeloma
2022-05-27
Cell and Gene Therapy Landscape in Japan is Moving Beyond Oncology
2022-05-27
New Study Reveals Hope for Recovery of Patients with Spinal Cord Injury
2022-05-27
Laekna Therapeutics Announces Dosing of First Patients in the U.S. and China in Phase Ib/III Study of Afuresertib in Combination with Fulvestrant in HR+/HER2- Breast Cancer
2022-05-26
Stanford Touts Remote-Controllable CAR-T Cell Therapy
2022-05-26
Phenomix Launches The First Obesity Biobank Registry To Study Underling Phenotypes
2022-05-26
EVENT
2022-06-03
ASCO Annual Meeting
Online and on-side
2022-06-07
Digital RESI June
Online
2022-06-09
Medhospafrica
Africa
2022-06-13
BIO International Convention
San Diego, CA
2022-12-14
BIOHK2022
Hong Kong, China
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!